Sandra Calvin - Feb 11, 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
SVP, CHIEF ACCOUNTING OFFICER
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Feb 11, 2025
Transactions value $
-$607,900
Form type
4
Date filed
2/12/2025, 09:27 PM
Previous filing
Feb 4, 2025
Next filing
Nov 6, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise $162K +10K +15.71% $16.23 73.7K Feb 11, 2025 Direct
transaction TVTX Common Stock Sale -$250K -10K -13.58% $25.00 63.7K Feb 11, 2025 Direct F1
transaction TVTX Common Stock Options Exercise $174K +10K +15.71% $17.44 73.7K Feb 11, 2025 Direct
transaction TVTX Common Stock Sale -$250K -10K -13.58% $25.00 63.7K Feb 11, 2025 Direct F2
transaction TVTX Common Stock Options Exercise $180K +10K +15.71% $17.96 73.7K Feb 11, 2025 Direct
transaction TVTX Common Stock Sale -$250K -10K -13.58% $25.00 63.7K Feb 11, 2025 Direct F3
transaction TVTX Common Stock Options Exercise $232K +15K +23.56% $15.46 78.7K Feb 11, 2025 Direct
transaction TVTX Common Stock Sale -$375K -15K -19.07% $25.00 63.7K Feb 11, 2025 Direct F4
transaction TVTX Common Stock Sale -$231K -9.24K -14.52% $25.00 54.4K Feb 11, 2025 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -10K -100% $0.00 0 Feb 11, 2025 Common Stock 10K $16.23 Direct F6
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -10K -100% $0.00 0 Feb 11, 2025 Common Stock 10K $17.44 Direct F6
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -10K -100% $0.00 0 Feb 11, 2025 Common Stock 10K $17.96 Direct F6
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -15K -100% $0.00 0 Feb 11, 2025 Common Stock 15K $15.46 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of May 19, 2026.
F2 This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of May 17, 2027.
F3 This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of May 9, 2029.
F4 This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of January 31, 2030.
F5 This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F6 The stock option is fully vested and exercisable.